CollaCote, CollaTape, CollaPlug, Absorbable Collagen Wound Dressings for Dental Surgery
Integra Lifesciences Corp. · Decision date Jun 4, 2026
What did the FDA decide?
FDA records P840062/S098 as a supplement to PMA P840062, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jun 4, 2026.
FDA approval order statement
replacement of the current bacterial endotoxin testing (BET) methods, Gel Clot and Kinetic Turbidimetric, with the Chromogenic method performed on the Endosafe Nexgen-MCS system
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Dental
- Decision date
- Jun 4, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P840062/S098
- Regulatory pathway
- PMA supplement
- Applicant
- Integra Lifesciences Corp.
- Product code
- LPG
- Decision code
- OK30
- Decision date
- Jun 4, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: MATERIAL, DRESSING, SURGICAL, POLYLACTIC ACID.
- Applicant
- Integra Lifesciences Corp.
- Product code
- LPG
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P840062. Subsequent supplements may change the device or its indications.
FDA decision timeline
P840062 · Original PMA
COLLACOTE(TM)
P840062/S098 received
Application receipt date recorded by FDA.
P840062/S097 · Related supplement
CollaCote and CollaTape Absorbable Collagen Wound Dressings for Dental Surgery
P840062/S098 · FDA decision
30-Day Notice
P840062/S099 · Related supplement
CollaCote, CollaTape, CollaPlug, Absorbable Collagen Wound Dressings for Dental Surgery
Timeline entries are records held by MedtechLedger for P840062. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P840062
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
COLLACOTE(TM)P840062 | Integra Lifesciences Corp. | PMA approval | Nov 8, 1985 | FDA |
| Integra Lifesciences Corp. | PMA supplement | May 27, 2026 | FDA | |
| Integra Lifesciences Corp. | PMA supplement | Sep 18, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Integra Lifesciences Corp.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 311 Enterprise Dr., Planisboro, NJ, 08536
Sources and methodology
- Original FDA record: P840062/S098
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
